MedTrace Logo

Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary Hypertension

NCT06350773 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-08-11

No results posted yet for this study

Summary

The goal of this clinical trial is to test the efficacy of tadalafil in patients with group II pulmonary hypertension with CpcPH with elevated pulmonary vascular resistance (PVR equals or more than 4 WU).

The main question it aims to answer is:

• Can tadalafil improve patients with group II pulmonary hypertension with CpcPH, regarding functional, clinical, biomarker and echocardiographic outcomes? Participants will undergo right heart catheterization (RHC) to make sure they are fulfilling the inclusion criteria of CpcPH, then will be asked to take tadalafil 20 mg for two weeks then 40 mg if tolerated for 12 weeks, then participants will be followed up. Investigators will compare the drug group with the control group.

Conditions

  • Group 2 Pulmonary Hypertension
  • CpcPH

Interventions

DRUG

tadalafil 20 mg then 40 mg if tolerated

Patients will receive tadalafil for 12 week follow up period

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Yasser Ahmed Abdelhady, Doctorate · Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-10
Primary Completion
2025-10-25
Completion
2025-10-25

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06350773 on ClinicalTrials.gov